SS-31 (Elamipretide): The Mitochondrial Peptide Targeting Cellular Senescence Mechanisms

If mitochondrial dysfunction is a central driver of cellular senescence, SS-31 is one of the most studied structural interventions. Developed in the early 2000s by Hazel Szeto at Weill Cornell Medical College and Peter Schiller (Zhao et al., 2004), SS-31 (also called Elamipretide, MTP-131, or Bendavia) is a cell-permeable tetrapeptide designed to accumulate at the inner mitochondrial membrane. It does not simply support mitochondrial function in a general sense. It targets a specific structural component, cardiolipin, that is essential for energy production and that deteriorates over the lifespan.

Why Cardiolipin Matters

Cardiolipin is a phospholipid found almost exclusively in the inner mitochondrial membrane. It is essential for the structural integrity and function of the electron transport chain (ETC) complexes, particularly Complex III and Complex IV. Cardiolipin also anchors cytochrome c, the electron carrier that shuttles electrons between complexes (Szeto, 2014).

When cardiolipin is oxidised or structurally altered (which happens progressively across the lifespan, and acutely in conditions like ischaemia-reperfusion injury), the ETC becomes less efficient. Electron leak increases, superoxide production rises, and a destructive cycle begins: oxidative damage to cardiolipin causes more electron leak, which causes more oxidative damage. This is one of the most well-characterised mechanisms of mitochondrial cellular senescence.

How SS-31 Works

SS-31 is a synthetic Szeto-Schiller peptide with the sequence D-Arg-Dmt-Lys-Phe-NH2 (where Dmt is 2',6'-dimethyltyrosine). Its mechanism is direct and structural:

• Cardiolipin Binding: SS-31 binds selectively to cardiolipin via electrostatic and hydrophobic interactions (Szeto, 2014). This stabilises the lipid's structure and helps prevent its peroxidation (Birk et al., 2013).
• ETC Optimisation: By maintaining cardiolipin integrity, SS-31 protects the structure of the mitochondrial cristae and supports efficient electron transport and oxidative phosphorylation (Szeto, 2014), reducing superoxide generation at source.
• Cytochrome c Stabilisation: SS-31 prevents cytochrome c from converting into a peroxidase (a transformation triggered by oxidised cardiolipin), which would otherwise amplify mitochondrial damage and trigger apoptosis (Birk et al., 2013).
• Mitochondrial Membrane Potential: Helped maintain membrane potential in damaged mitochondria in cell studies (Zhao et al., 2004), and improved the efficiency of ATP production in aged mouse muscle (Siegel et al., 2013).

SS-31 was first described as a mitochondria-targeted antioxidant: its dimethyltyrosine residue can scavenge some reactive oxygen species directly (Zhao et al., 2004; Szeto, 2006). Later work emphasises a different main action: by binding cardiolipin and maintaining mitochondrial architecture, it limits excessive ROS generation in the first place (Szeto, 2014). This upstream approach distinguishes it from compounds like MitoQ or CoQ10.

Preclinical Evidence in Cellular Senescence Models

The cellular senescence data on SS-31 is some of the most compelling in mitochondrial medicine. In multiple animal models:

• Heart: Eight weeks of SS-31 treatment substantially reversed age-related diastolic dysfunction in old mice, with reduced proton leak and mitochondrial ROS in heart muscle cells (Chiao et al., 2020).
• Skeletal Muscle: A single treatment restored mitochondrial energetics in aged mouse muscle to young levels within an hour and made the muscle more fatigue resistant (Siegel et al., 2013). Eight weeks of treatment in aged mice improved exercise tolerance and redox balance in skeletal muscle (Campbell et al., 2019).
• Kidney: Eight weeks of SS-31 in 24-month-old mice improved mitochondrial structure in kidney glomeruli and reduced age-related glomerulosclerosis and senescence markers (Sweetwyne et al., 2017).
• Brain: In cultured neurons from an Alzheimer's disease mouse model, SS-31 restored mitochondrial transport and synaptic viability and reduced amyloid-beta-induced mitochondrial damage (Calkins et al., 2011), though it has not been tested in human trials for Alzheimer's disease.

A particularly striking finding was that many of these age-related changes were reversed within an hour to weeks, not just slowed. This suggests that mitochondrial architecture can be restored even in older tissue, challenging the assumption that mitochondrial decline is irreversible.

Clinical Trials and Barth Syndrome

SS-31 has been most advanced clinically in Barth syndrome, a rare X-linked genetic disorder caused by mutations in the tafazzin (TAZ) gene. Tafazzin is the enzyme responsible for cardiolipin remodelling, so Barth syndrome patients have fundamentally abnormal cardiolipin, leading to cardiomyopathy, skeletal myopathy, neutropenia, and growth failure.

In the TAZPOWER trial (12 patients), the 12-week placebo-controlled crossover phase did not meet its primary endpoints of six-minute walk distance and a symptom score. In the open-label extension, six-minute walk distance, symptom scores, knee extensor strength and some cardiac measures improved (Reid Thompson et al., 2021), and the walking gains were maintained to 168 weeks in the eight patients who reached that point (Thompson et al., 2024). The FDA granted Fast Track and Orphan Drug designation for this indication (company announcement), and on 19 September 2025 granted elamipretide accelerated approval to improve muscle strength in Barth syndrome patients weighing at least 30 kg, based on improved knee extensor strength (FDA approval package). Continued approval depends on a confirmatory trial; a placebo-controlled Phase 3b/4 study began recruiting in July 2026 (ClinicalTrials.gov NCT07531251).

Beyond Barth syndrome, clinical trials have explored SS-31 in:

• Heart failure with reduced ejection fraction (HFrEF): The PROGRESS-HF phase 2 trial (71 patients) found no improvement in left ventricular end-systolic volume or ejection fraction after 4 weeks (Butler et al., 2020).
• Primary mitochondrial myopathy: A Phase 1/2 trial found a dose-dependent increase in six-minute walk distance after 5 days (Karaa et al., 2018), but the Phase 3 MMPOWER-3 trial (218 participants) did not meet its primary endpoints of walking distance and fatigue (Karaa et al., 2023).
• Kidney ischaemia-reperfusion: In a 14-patient pilot trial, elamipretide given during stenting for renal artery stenosis was associated with less kidney hypoxia after the procedure and better kidney blood flow and function at 3 months (Saad et al., 2017).

SS-31 and the Cellular Senescence Field

SS-31 sits at the intersection of cellular senescence science and mitochondrial medicine. Its relevance to this research is grounded in the mitochondrial theory of cellular senescence, which holds that progressive mitochondrial dysfunction drives many recognised hallmarks: genomic instability, cellular senescence, stem cell exhaustion, and chronic inflammation.

Compared to other mitochondrial interventions:

• NAD+ precursors (NMN/NR) support mitochondrial function by replenishing a critical cofactor. SS-31 works structurally on the membrane itself. The two approaches are complementary.
• MOTS-c is an endogenous mitochondrial signalling peptide that activates AMPK. SS-31 is a synthetic peptide that targets mitochondrial ultrastructure. Together, they represent signalling and structural approaches to mitochondrial health.
• Urolithin A promotes mitophagy (clearance of damaged mitochondria). SS-31 rescues existing mitochondria. One removes the broken, the other repairs the salvageable.
• CoQ10 and MitoQ act as electron carriers and antioxidants. SS-31 prevents the need for downstream antioxidant defence by maintaining efficient electron transport upstream.

Clinical Delivery and Cell Uptake

Clinical trials of SS-31 have delivered it by subcutaneous injection or intravenous infusion. The peptide has high cell permeability due to its alternating aromatic-cationic motif, which allows it to cross lipid bilayers and concentrate more than 1,000-fold in the inner mitochondrial membrane in cell studies (Zhao et al., 2004; Szeto, 2006).

Research-grade SS-31 is available through peptide suppliers, but it is not an approved medicine: in the US, elamipretide is approved only as a prescription treatment for Barth syndrome.

Safety Profile

In clinical trials, including the 218-participant MMPOWER-3 study, SS-31 has generally been reported as well tolerated (Karaa et al., 2023), with injection site reactions the most common adverse events (Karaa et al., 2020). However, the FDA label for the approved product warns of hypersensitivity reactions, including serious allergic reactions that needed emergency treatment, and notes temporary rises in eosinophil counts (FDA label). Long-term data come from very small groups: in the Barth syndrome programme, eight patients were treated for 168 weeks.

The Bottom Line

SS-31 is one of the most mechanistically precise peptides in the cellular senescence space. Rather than broadly supporting mitochondrial health, it targets a specific structural vulnerability, cardiolipin degradation, that sits at the root of age-related mitochondrial dysfunction. The preclinical data showing reversal (not just prevention) of age-related organ decline is notable, and its 2025 accelerated approval in Barth syndrome, which still requires a confirmatory trial, provides a pathway to human validation. For researchers tracking the intersection of peptide science and cellular senescence biology, SS-31 remains a compound of interest.

References

1. Birk AV, et al. (2013). The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology. PubMed 23813215
2. Butler J, et al. (2020). Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. Journal of Cardiac Failure. PubMed 32068002
3. Calkins MJ, et al. (2011). Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. Human Molecular Genetics. PubMed 21873260
4. Campbell MD, et al. (2019). Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice. Free Radical Biology and Medicine. PubMed 30597195
5. Chiao YA, et al. (2020). Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice. eLife. PubMed 32648542
6. Karaa A, et al. (2018). Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. PubMed 29500292
7. Karaa A, et al. (2020). A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. Journal of Cachexia, Sarcopenia and Muscle. PubMed 32096613
8. Karaa A, et al. (2023). Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology. PubMed 37268435
9. Reid Thompson W, et al. (2021). A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genetics in Medicine. PubMed 33077895
10. Roshanravan B, et al. (2021). In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial. PLoS ONE. PubMed 34264994
11. Saad A, et al. (2017). Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis. Circulation: Cardiovascular Interventions. PubMed 28916603
12. Siegel MP, et al. (2013). Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell. PubMed 23692570
13. Sweetwyne MT, et al. (2017). The mitochondrial-targeted peptide, SS-31, improves glomerular architecture in mice of advanced age. Kidney International. PubMed 28063595
14. Szeto HH. (2006). Cell-permeable, mitochondrial-targeted, peptide antioxidants. The AAPS Journal. PubMed 16796378
15. Szeto HH. (2014). First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology. PubMed 24117165
16. Thompson WR, et al. (2024). Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genetics in Medicine. PubMed 38602181
17. Zhao K, et al. (2004). Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. Journal of Biological Chemistry. PubMed 15178689